Cargando…
XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States
INTRODUCTION: The purpose of this study was to evaluate intraocular pressure (IOP) lowering and safety of XEN(®) stent in medically refractory, progressive, open-angle glaucoma (OAG). METHODS: Forty-seven eyes of 42 patients were treated with XEN(®) stent alone or combined with phacoemulsification....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692422/ https://www.ncbi.nlm.nih.gov/pubmed/31197608 http://dx.doi.org/10.1007/s40123-019-0192-8 |
_version_ | 1783443548779053056 |
---|---|
author | Kalina, Andrew G. Kalina, Paul H. Brown, Morgan M. |
author_facet | Kalina, Andrew G. Kalina, Paul H. Brown, Morgan M. |
author_sort | Kalina, Andrew G. |
collection | PubMed |
description | INTRODUCTION: The purpose of this study was to evaluate intraocular pressure (IOP) lowering and safety of XEN(®) stent in medically refractory, progressive, open-angle glaucoma (OAG). METHODS: Forty-seven eyes of 42 patients were treated with XEN(®) stent alone or combined with phacoemulsification. RESULTS: Mean IOP decreased from 22.34 ± 7.34 mmHg to 12.91 ± 4.21, 12.95 ± 4.36, 13.49 ± 3.91, and 13.36 ± 3.63 mmHg at 1, 3, 6, and 12 months (95% confidence interval [CI] [20.24, 24.44], [11.71, 14.12], [11.63, 14.27], [12.36, 14.62], and [12.10, 14.62]), respectively. Mean number of medications decreased from 2.96 ± 1.20 (95% CI [2.62, 3.30]) at baseline to 0.75 ± 1.27 (95% CI [0.31, 1.19]) at 1 year. At 1 year (n = 32), complete success was achieved in 68.8% (n = 22/32) (i.e., IOP reduction ≥ 20% and IOP < 18 mmHg without medication or any secondary glaucoma intervention). Qualified success was achieved in 90.6% (n = 29/32) (i.e., IOP reduction of ≥ 20% and IOP < 18 mmHg with and without medication or any secondary glaucoma intervention). Eleven eyes had not yet reached 12 months. Two patients (three eyes) died before 1 year; one patient (one eye) was lost to follow up. Adverse events: localized choroidal hemorrhage in one eye; hypotony (IOP < 6 mmHg) at day 1 in 10 eyes, with full resolution by 2 weeks. No persistent hypotony or maculopathy occurred. Stent erosion with removal occurred in two eyes. Fourteen eyes (29.8%) underwent needling. One patient required trabeculectomy. CONCLUSIONS: XEN(®) stent is effective and relatively safe surgery for medically refractory, progressive, OAG out to 1 year. Intraocular pressure and medications were significantly reduced. |
format | Online Article Text |
id | pubmed-6692422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-66924222019-08-26 XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States Kalina, Andrew G. Kalina, Paul H. Brown, Morgan M. Ophthalmol Ther Original Research INTRODUCTION: The purpose of this study was to evaluate intraocular pressure (IOP) lowering and safety of XEN(®) stent in medically refractory, progressive, open-angle glaucoma (OAG). METHODS: Forty-seven eyes of 42 patients were treated with XEN(®) stent alone or combined with phacoemulsification. RESULTS: Mean IOP decreased from 22.34 ± 7.34 mmHg to 12.91 ± 4.21, 12.95 ± 4.36, 13.49 ± 3.91, and 13.36 ± 3.63 mmHg at 1, 3, 6, and 12 months (95% confidence interval [CI] [20.24, 24.44], [11.71, 14.12], [11.63, 14.27], [12.36, 14.62], and [12.10, 14.62]), respectively. Mean number of medications decreased from 2.96 ± 1.20 (95% CI [2.62, 3.30]) at baseline to 0.75 ± 1.27 (95% CI [0.31, 1.19]) at 1 year. At 1 year (n = 32), complete success was achieved in 68.8% (n = 22/32) (i.e., IOP reduction ≥ 20% and IOP < 18 mmHg without medication or any secondary glaucoma intervention). Qualified success was achieved in 90.6% (n = 29/32) (i.e., IOP reduction of ≥ 20% and IOP < 18 mmHg with and without medication or any secondary glaucoma intervention). Eleven eyes had not yet reached 12 months. Two patients (three eyes) died before 1 year; one patient (one eye) was lost to follow up. Adverse events: localized choroidal hemorrhage in one eye; hypotony (IOP < 6 mmHg) at day 1 in 10 eyes, with full resolution by 2 weeks. No persistent hypotony or maculopathy occurred. Stent erosion with removal occurred in two eyes. Fourteen eyes (29.8%) underwent needling. One patient required trabeculectomy. CONCLUSIONS: XEN(®) stent is effective and relatively safe surgery for medically refractory, progressive, OAG out to 1 year. Intraocular pressure and medications were significantly reduced. Springer Healthcare 2019-06-13 2019-09 /pmc/articles/PMC6692422/ /pubmed/31197608 http://dx.doi.org/10.1007/s40123-019-0192-8 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Kalina, Andrew G. Kalina, Paul H. Brown, Morgan M. XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title | XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title_full | XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title_fullStr | XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title_full_unstemmed | XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title_short | XEN(®) Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States |
title_sort | xen(®) gel stent in medically refractory open-angle glaucoma: results and observations after one year of use in the united states |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692422/ https://www.ncbi.nlm.nih.gov/pubmed/31197608 http://dx.doi.org/10.1007/s40123-019-0192-8 |
work_keys_str_mv | AT kalinaandrewg xengelstentinmedicallyrefractoryopenangleglaucomaresultsandobservationsafteroneyearofuseintheunitedstates AT kalinapaulh xengelstentinmedicallyrefractoryopenangleglaucomaresultsandobservationsafteroneyearofuseintheunitedstates AT brownmorganm xengelstentinmedicallyrefractoryopenangleglaucomaresultsandobservationsafteroneyearofuseintheunitedstates |